HOOKIPA Pharma Inc. (HOOK)
HOOK Stock Price Chart
Explore HOOKIPA Pharma Inc. interactive price chart. Choose custom timeframes to analyze HOOK price movements and trends.
HOOK Company Profile
Discover essential business fundamentals and corporate details for HOOKIPA Pharma Inc. (HOOK) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
18 Apr 2019
Employees
82.00
Website
https://www.hookipapharma.comCEO
Malte Peters
Description
HOOKIPA Pharma Inc., a clinical stage biopharmaceutical company, develops immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform. The company's lead infectious disease product candidate is HB-101, which is in a randomized double-blinded Phase II clinical trial in patients awaiting kidney transplantation from cytomegalovirus-positive donors. Its lead oncology product candidates are HB-201 and HB-202 that are in Phase I/II clinical trial for the treatment of human papillomavirus 16-positive cancers. The company's preclinical stage products include HB-300 program for prostate cancer; and HB-700 for targeting mutated KRAS in pancreatic, colorectal, and lung cancer. HOOKIPA Pharma Inc. has a collaboration with Gilead Sciences, Inc. to collaborate on preclinical research programs to evaluate potential vaccine products using or incorporating its replicating and non-replicating technology platforms for the treatment, cure, diagnosis, or prevention of Hepatitis B Virus. The company was incorporated in 2011 and is headquartered in New York, New York.
HOOK Financial Timeline
Browse a chronological timeline of HOOKIPA Pharma Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 13 May 2026
Upcoming earnings on 26 Feb 2026
Upcoming earnings on 12 Nov 2025
Earnings released on 14 Aug 2025
EPS came in at -$1.52 falling short of the estimated -$0.64 by -137.50%.
Earnings released on 15 May 2025
EPS came in at -$1.23 falling short of the estimated -$0.61 by -101.64%, while revenue for the quarter reached $2.00M , missing expectations by -40.62%.
Earnings released on 27 Feb 2025
EPS came in at -$1.96 falling short of the estimated -$0.41 by -378.05%, while revenue for the quarter reached $1.35M , missing expectations by -60.61%.
Earnings released on 14 Nov 2024
EPS came in at -$1.10 surpassing the estimated -$1.28 by +14.06%, while revenue for the quarter reached $4.70M , missing expectations by -24.75%.
Earnings released on 8 Aug 2024
EPS came in at -$1.52 falling short of the estimated -$1.44 by -5.56%, while revenue for the quarter reached $1.29M , missing expectations by -78.75%.
Stock split effective on 10 Jul 2024
Shares were split 1 : 10 , changing the number of shares outstanding and the price per share accordingly.
Earnings released on 9 May 2024
EPS came in at $1.20 surpassing the estimated -$1.20 by +200.00%, while revenue for the quarter reached $36.60M , beating expectations by +1.21K%.
Earnings released on 22 Mar 2024
EPS came in at -$1.10 surpassing the estimated -$2.00 by +45.00%, while revenue for the quarter reached $7.41M , beating expectations by +62.79%.
Earnings released on 9 Nov 2023
EPS came in at -$1.70 surpassing the estimated -$2.30 by +26.09%, while revenue for the quarter reached $6.87M , beating expectations by +50.92%.
Earnings released on 10 Aug 2023
EPS came in at -$2.20 falling short of the estimated -$2.10 by -4.76%, while revenue for the quarter reached $2.68M , missing expectations by -44.99%.
Earnings released on 11 May 2023
EPS came in at -$2.70 falling short of the estimated -$2.40 by -12.50%, while revenue for the quarter reached $3.18M , missing expectations by -27.65%.
Earnings released on 15 Mar 2023
EPS came in at -$1.70 surpassing the estimated -$1.80 by +5.56%, while revenue for the quarter reached $7.83M , beating expectations by +10.72%.
Earnings released on 14 Nov 2022
EPS came in at -$2.50 falling short of the estimated -$2.40 by -4.17%, while revenue for the quarter reached $2.23M , missing expectations by -23.31%.
Earnings released on 11 Aug 2022
EPS came in at -$2.30 surpassing the estimated -$3.60 by +36.11%, while revenue for the quarter reached $2.75M , missing expectations by -18.18%.
Earnings released on 16 May 2022
EPS came in at -$4.00 falling short of the estimated -$1.20 by -233.33%, while revenue for the quarter reached $1.45M , missing expectations by -90.06%.
Earnings released on 24 Mar 2022
EPS came in at -$6.50 falling short of the estimated -$5.30 by -22.64%, while revenue for the quarter reached $3.90M , beating expectations by +2.38%.
Earnings released on 10 Nov 2021
EPS came in at -$6.10 falling short of the estimated -$5.40 by -12.96%, while revenue for the quarter reached $3.87M , beating expectations by +14.89%.
Earnings released on 12 Aug 2021
EPS came in at -$5.20 matching the estimated -$5.20, while revenue for the quarter reached $5.38M , beating expectations by +4.83%.
Earnings released on 12 May 2021
EPS came in at -$5.30 matching the estimated -$5.30, while revenue for the quarter reached $5.30M , meeting expectations.
Earnings released on 18 Mar 2021
EPS came in at -$4.60 surpassing the estimated -$5.60 by +17.86%, while revenue for the quarter reached $5.16M .
Earnings released on 12 Nov 2020
EPS came in at -$5.30 falling short of the estimated -$4.20 by -26.19%, while revenue for the quarter reached $4.04M , beating expectations by +30.30%.
HOOK Stock Performance
Access detailed HOOK performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.